Cryo-Cell International Inc
cryo-cell.comWhat Do They Do?
Processes and stores umbilical cord blood and tissue stem cells for families, and supplies public-bank cord blood to transplant centers through a distribution partner.
10-K for FY2025, filed Feb 27, 2026Cryo-Cell International, Inc. (the “Company” or “Cryo-Cell”) is a Delaware corporation that was incorporated in 1989. The Company is…View ↗
Stem cells are found in umbilical cord blood (“cord blood stem cells”) and can be collected and stored after a baby is born. Over 60,000…View ↗
In June 2018, the Company acquired substantially all of the assets (the “Cord Purchase”) of Cord:Use Cord Blood Bank, Inc., a Florida…View ↗
How Do They Make Money?
Families generally pay for processing, testing and first-year storage when specimens are processed; later storage is billed annually unless prepaid under a longer plan. The company also receives cost recovery when public-bank units are distributed for transplant.
10-K for FY2025, filed Feb 27, 2026The Company enters into storage agreements with its clients under which the Company charges a fee for the processing and testing and first…View ↗
The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets…View ↗
Upon execution of the acquisition of all of the assets of Cord:Use, the Company acquired the cord blood operations which included both…View ↗
-
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗
$31.6M
-
10-K for FY2025, filed Feb 27, 2026
$31.6M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Processing and Storage Fees
|
99%
FY2022: 98%
|
Processing and Storage Fees, FY2025
$31.4M Sources
|
|
|
Public Banking
Sold outright
|
0.4%
FY2022: 1.5%
|
Public Banking, FY2025
$129.5K Sources
|
Sold outright |
|
Product
|
0.2%
FY2022: 0.3%
|
Product, FY2025
$54.1K Sources
|
Who Are Their Customers?
Families can enroll online; medical professionals refer expectant parents. Public-bank units go through the National Marrow Donor Program to transplant centers.
10-K for FY2025, filed Feb 27, 2026The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through…View ↗
The Company continues to use its website, www.cryo-cell.com, to market its services and to provide resource information to expectant…View ↗
In June 2018, the Company acquired substantially all of the assets (the “Cord Purchase”) of Cord:Use Cord Blood Bank, Inc., a Florida…View ↗
Do Revenues Turn Into Profits?
Not on paper. It lost $2.4M in FY2025, but brought in more cash than it spent: $5.2M of free cash flow.
10-K for FY2025, filed Feb 27, 2026
$482.4KView ↗
10-K for FY2025, filed Feb 27, 2026
−$2.4MView ↗
10-K for FY2025, filed Feb 27, 2026
$5.2MView ↗
How Are They Changing?
10-Q for Q3 FY2026, filed Oct 9, 2026
Open tableView ↗
-
May 8, 2026
NYSE American accepts plan to regain listing compliance
The stock remains listed during the plan period, which runs through September 9, 2027.
Sources
8-K, filed May 8, 2026
As previously disclosed, the Company submitted a compliance plan to NYSE American on April 8, 2026. NYSE Regulation accepted the plan and…View ↗
-
Mar 12, 2026
NYSE American notifies Cryo-Cell of listing-rule noncompliance
The notice had no immediate effect on trading while the company pursued a compliance plan.
Sources
8-K, filed Mar 12, 2026
On March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE…View ↗
Growing. Revenue grew 9% in 4 years, from $28.9M in FY2021 to $31.6M in FY2025, about 2% a year.
Loading...
